Drug Target Review

DECEMBER 28, 2023

These newly formed mutated proteins are called neoantigens and they are only present on tumour cells and are not found in normal, healthy cells. These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Drug Target Review

OCTOBER 2, 2023

Immunopeptidomics is a rapidly expanding field at the intersection of immunology and proteomics that focuses on the identification and characterization of peptides presented by major histocompatibility complex (MHC) molecules, also known as the human leukocyte antigen (HLA), on cell surfaces. Research Square. 2023 [cited 2023 Sep 21].

Immune Response 105

Immune Response Vaccine Disease Research 105

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

SugarCone Biotech

JUNE 10, 2024

Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immune responses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immune responses.

Immune Response 87

Immune Response Production Regulations Clinical Trials 87

Drug Target Review

SEPTEMBER 5, 2023

Following this, they play a vital role in stimulating the adaptive immune response for more robust defence by displaying fragments of protein from the intruders, known as antigens, on their surface. These antigens, showcased on macrophages by a carrier protein called MHCII, activate T cells, pivotal components of the immune response.

Disease 98

Disease Immune Response Research 98

SugarCone Biotech

MARCH 24, 2025

These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. The blueprint reveals the structure of a productive T cell immune synapse cell surface and the proteins involved (Figure 1).

Immune Response 64

Immune Response Therapies Treatment Disease 64

Chemical Biology and Drug Design

FEBRUARY 2, 2024

Terpenes are compounds that inhibit the growth of Leishmania spp, Schistosoma spp, and Echinococcus spp, cause changes in parasite ultrastructure, inhibit enzyme activity, and modulate the immune response. Their use in combination therapy decreases the concentration of the reference drug used.

Treatment 100

Treatment Disease Immune Response Therapies 100

Drug Target Review

MARCH 1, 2024

In this study , we demonstrated that AMP immunotherapy can boost TCR-T cell therapy by acting directly in the lymph nodes to promote the coordination of tumour-specific T cell responses by antigen presenting cells. This combination approach resulted in durable anti-tumour T cell responses and tumour eradication.

Immune Response 105

Immune Response Therapies Vaccine Small Molecule 105

DrugBank

JULY 18, 2024

Adjuvants are substances added to vaccines to enhance the immune response. They work by decreasing the solubility of the vaccine, which sustains the release of the drug and prolongs the immune response. Even after a vaccine is approved and distributed, the pharmaceutical industry's responsibility does not end.

Vaccine 98

Vaccine Immune Response Clinical Trials Disease 98

Drug Target Review

NOVEMBER 24, 2023

2 Previously, La-Beck’s research has shown that liposomes made of phospholipids and cholesterol, like those used in patients, doubled tumour size in mice by suppressing their immune response in some tumours. Macrophages were detected as the cells responsible for these negative effects.

Immune Response 111

Immune Response Pharmacy Treatment Virus 111

The Pharma Data

OCTOBER 6, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

The Pharma Data

JUNE 29, 2021

A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. There is an excellent response to a second dose, even after a 10 month delay from the first.”.

Immune Response 52

Immune Response Vaccine Virus Trials 52

Chemical Biology and Drug Design

JANUARY 29, 2024

To aid the medicinal chemist in the design of sPLA 2 inhibitors, this review selected four human sPLA 2 s and presented the characteristics of the bound inhibitors that are considered key for high-affinity interaction. Due to their roles in inflammation, the sPLA 2 enzymes are of much medicinal interest.

Small Molecule 100

Small Molecule Immune Response Treatment Disease 100

The Pharma Data

OCTOBER 9, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

Chemical Biology and Drug Design

APRIL 28, 2023

Additionally, our research sought to present a modeled structure of a few putative virulence factors that might aid in the development of new chemotherapeutic approaches for the treatment of leishmaniasis.

Immune Response 100

Immune Response Vaccine Treatment Disease 100

Codon

NOVEMBER 3, 2024

During vaccination, the BCG strain normally primes immune cells to destroy infections, and owing to its similarity to M. tuberculosis , the same immune cells cross-react with the pathogen. It is responsible for over one million deaths per year (and is projected to rise ten times over by 2050). tuberculosis.

Vaccine 98

Vaccine Trials Therapies Treatment 98

Broad Institute

OCTOBER 11, 2023

He also read everything he could about her disease, including emerging evidence that suggested that the immune system could recognize and kill Merkel cell carcinoma. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137

Research Immune Response Clinical Trials Therapies 137

Drug Target Review

DECEMBER 27, 2023

This interaction inhibits inflammation and immune activation, and in particular prevents macrophages from phagocytosing and destroying cancer cells. By blocking CD24 with an antibody drug, our goal is to powerfully reactivate the anti-cancer immune response and drive therapeutic efficacy.

Immune Response 105

Immune Response Science Clinical Development Drugs 105

Drug Target Review

JANUARY 2, 2024

In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immune responses. In the lab, they labelled RNA molecules with fluorescent markers, enabling them to easily locate them within individual cells.

RNA 128

RNA Immune Response Therapies Disease 128

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Target Review

OCTOBER 19, 2023

A potential game-changer in medicine The implications of this research are vast, potentially transforming the way we treat a variety of diseases involving both the immune and nervous systems. In the absence of IL-31, these nerve cells failed to control the immune system, leading to unchecked inflammation.

Immune Response 104

Immune Response Regulations Treatment Therapies 104

Drug Target Review

JANUARY 15, 2024

An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell. Figure 1: HLA Class I presentation of peptides derived from intracellular antigens. However, most of these peptides may also be presented by normal cells.

Engineering 110

Engineering DNA Virus Immune Response 110

Drug Target Review

SEPTEMBER 11, 2023

While the concept of removing mucins from cancer cells seems promising, mucins are present in various forms on all mammalian cells. This sugar-coated mucin binding to checkpoint receptors signals that the cancer cell poses no threat, consequently blocking the immune response.

Immune Response 116

Immune Response Research Engineering Virus 116

Drug Target Review

JUNE 6, 2023

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

SEPTEMBER 8, 2021

“We are pleased to present additional analyses for LUMAKRAS, our newly approved KRAS G12C inhibitor, as well as a trial-in-progress poster for acapatamab, our investigational BiTE molecule being studied in NSCLC and other solid tumors. Reese, M.D., executive vice president of Research and Development at Amgen.

Trials 52

Trials Clinical Trials Therapies Treatment 52

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Target Review

JANUARY 15, 2024

The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases. Dr Yuri concluded: “We believe that our study makes an important contribution to the literature by presenting a faster and more efficient method of exploring blastocyst complementation.”

Immune Response 113

Immune Response Disease Science Therapies 113

Drug Target Review

SEPTEMBER 9, 2024

functions to reset the immune system and potentially provide remission for allergic diseases? 1104 acts upstream in the inflammatory response, targeting one of the first key players: antigen-presenting cells (APCs). In allergic diseases, APCs identify and present unknown antigens to the immune system.

Disease 64

Disease Immune Response Clinical Trials Treatment 64

Drug Target Review

JANUARY 15, 2024

Additionally, in evaluating the effectiveness of our initial pipeline asset, we sought tumours suitable for intratumoural injection that present surface-accessible lesions. The preclinical results demonstrated significant immune responses and tumour regression. Activation of the ELANE pathway appears pivotal.

Treatment 105

Treatment Immune Response Therapies Clinical Trials 105

Drug Target Review

MAY 14, 2024

How do hydrophobicity, electrostatic charge, and secondary confirmation of helical polypeptides influence the stimulation of innate immune pathways in antigen-presenting cells (APCs)? What potential therapeutic advantages do the engineered cationic polypeptides offer in the context of generating antitumour immune responses?

Engineering 59

Engineering Immune Response FDA Approval Clinical Trials 59

Drug Target Review

OCTOBER 4, 2023

More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. This approach – immune-stimulating antibody conjugates (ISACs) – uses a payload that stimulates the innate and adaptive immune responses, recruiting tumour-fighting T cells.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

DECEMBER 13, 2023

This is likely indicative of the heterogeneous nature of the disorder, and it is this complexity and diversity of clinical presentation and effects across multiple organ systems, that has made efforts to identify genetic risk factors using traditional genomic analysis approaches extremely challenging.

Bioinformatics 145

Bioinformatics Disease Regulations Immune Response 145

NIH Director's Blog: Drug Development

JUNE 30, 2020

But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response. Three neutralized the virus even when present at extremely low levels, and they now will be studied further as possible monoclonal antibodies. But again, not all antibodies are created equal.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

MAY 15, 2023

Bexsero is used as the comparator for the MenB immune responses induced by the MenABCWY vaccine in the trial, which is both the phase III trial for MenABCWY and confirmatory trial for Bexsero in the US. There are a total of 11 primary endpoints for the trial, five for MenABCWY and six for Bexsero.

Vaccine 40

Vaccine Immune Response Licensing Licensing 40

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. About Novavax.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

OCTOBER 19, 2020

Two presentations will be delivered by Nanobiotix and two will be delivered by the University of Texas MD Anderson Cancer Center. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.

Clinical Trials 40

Clinical Trials Immune Response Trials Therapies 40

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52